Merck's Sotatercept Study for Pulmonary Arterial Hypertension Launches in India
Merck Sharp & Dohme is conducting a study to evaluate the safety and tolerability of sotatercept in combination with standard treatments for PAH in India.
Therapeutic Area
Therapeutic area intelligence for Pulmonary Arterial Hypertension with 8 indexed intelligence signals across regulatory, clinical, competitive, and market developments.
No catalysts indexed for this entity yet.
No related entities indexed yet.
Newsletter
Concise strategic intelligence on regulatory, clinical, competitive, and market developments — free to subscribe.
No paywall. No spam. Unsubscribe anytime.